Patents by Inventor Michael N. Pollak

Michael N. Pollak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bispecific oligonucleotide for the treatment of CNS malignancies
    Patent number: 8168610
    Abstract: CNS malignancy is treated in a subject suffering from a CNS malignancy by administering to the subject an antisense oligonucleotide having a sequence of bases that is complementary to portions of both the gene encoding IGFBP-2 and the gene encoding IGFBP-5, and which is of sufficient length to act as an inhibitor of the effective amount of IGFBP-2 and IGFBP-5, in an amount effective to reduce effective levels of IGFBP-2 and IGFBP-5 in cells of the CNS malignancy.
    Type: Grant
    Filed: January 11, 2011
    Date of Patent: May 1, 2012
    Assignee: The University of British Columbia
    Inventors: Martin Gleave, Michael N. Pollak, Randy J. Leavitt
  • Bispecific Oligonucleotide for the Treatment of CNS Malignancies
    Publication number: 20110152354
    Abstract: CNS malignancy is treated in a subject suffering from a CNS malignancy by administering to the subject an antisense oligonucleotide having a sequence of bases that is complementary to portions of both the gene encoding IGFBP-2 and the gene encoding IGFBP-5, and which is of sufficient length to act as an inhibitor of the effective amount of IGFBP-2 and IGFBP-5, in an amount effective to reduce effective levels of IGFBP-2 and IGFBP-5 in cells of the CNS malignancy.
    Type: Application
    Filed: January 11, 2011
    Publication date: June 23, 2011
    Applicant: THE UNIVERSITY OF BRITISH COLUMBIA
    Inventors: Martin E. Gleave, Michael N. Pollak, Randy J. Levitt
  • Bispecific oligonucleotide for the treatment of CNS malignancies
    Patent number: 7932234
    Abstract: CNS malignancy is treated in a subject suffering from a CNS malignancy by administering to the subject an antisense oligonucleotide having a sequence of bases that is complementary to portions of both the gene encoding IGFBP-2 and the gene encoding IGFBP-5, and which is of sufficient length to act as an inhibitor of the effective amount of IGFBP-2 and IGFBP-5, in an amount effective to reduce effective levels of IGFBP-2 and IGFBP-5 in cells of the CNS malignancy.
    Type: Grant
    Filed: May 13, 2005
    Date of Patent: April 26, 2011
    Assignee: The University of British Columbia
    Inventors: Martin E. Gleave, Michael N. Pollak, Randy J. Levitt
  • Circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3 and prostate cancer risk
    Patent number: 6645770
    Abstract: Methods of predicting a propensity to developing prostate cancer are presented. The method consists of measuring the IGF status of individual. Individuals with high IGF status, as compared with normal reference range values, are at increased risk for developing prostate cancer. More particularly, the IGF status may be determined by measuring IGF-I levels and/or IGFBP-3 levels. High IGF and low IGFBP levels are indicative of a high IGF status. A method of determining the prognosis of existing prostate cancers or of monitoring disease progression involves determining the IGF/PSA status of an individual. Individuals with a high IGF/PSA status (both high IGF status and high PSA levels) tend to develop severe prostate cancer and have a poorer overall prognosis.
    Type: Grant
    Filed: March 14, 2001
    Date of Patent: November 11, 2003
    Assignees: The Brigham & Women's Hospital, Inc., Lady Davis Institute
    Inventors: Michael N. Pollak, Meir J. Stampfer, Edward Giovannucci
  • Circulating insulin-like growth factor-I and prostate cancer risk
    Publication number: 20030044860
    Abstract: Methods of predicting a propensity to developing prostate cancer are presented. The method consists of measuring the IGF status of individual. Individuals with high IGF status, as compared with normal reference range values, are at increased risk for developing prostate cancer. More particularly, the IGF status may be determined by measuring IGF-I levels and/or IGFBP-3 levels. High IGF and low IGFBP levels are indicative of a high IGF status. A method of determining the prognosis of existing prostate cancers or of monitoring disease progression involves determining the IGF/PSA status of an individual. Individuals with a high IGF/PSA status (both high IGF status and high PSA levels) tend to develop severe prostate cancer and have a poorer overall prognosis.
    Type: Application
    Filed: December 18, 2001
    Publication date: March 6, 2003
    Applicant: Lady Davis Institute
    Inventors: Michael N. Pollak, Meir J. Stampfer, Edward Giovannucci
  • Circulating insulin-like growth factor-I and prostate cancer risk
    Patent number: 6410335
    Abstract: Methods of predicting a propensity to developing prostate cancer are presented. The consists of measuring the IGF status of individual. Individuals with high IGF status, as compared with normal reference range values, are at increased risk for developing prostate cancer. More particularly, the IGF status may be determined by measuring IGF-I levels and/or IGFBP-3 levels. High IGF and low IGFBP levels are indicative of a high IGF status. A method of determining the prognosis of existing prostate cancers or of monitoring disease progression involves determining the IGF/PSA status of an individual. Individuals with a high IGF/PSA staus (both high IGF status and high PSA levels) tend to develop severe prostate cancer and have a porrer overall prognosis.
    Type: Grant
    Filed: January 21, 1999
    Date of Patent: June 25, 2002
    Assignees: The Brigham and Woman's Hospital, Inc., Sir Mortimer B. Davis - Jewish General Hospital Foundation
    Inventors: Michael N. Pollak, Meir J. Stampfer, Edward Giovannucci
  • Circulating insulin-like growth factor-I and prostate cancer risk
    Publication number: 20010018190
    Abstract: Methods of predicting a propensity to developing prostate cancer are presented. The method consists of measuring the IGF status of individual. Individuals with high IGF status, as compared with normal reference range values, are at increased risk for developing prostate cancer. More particularly, the IGF status may be determined by measuring IGF-I levels and/or IGFBP-3 levels. High IGF and low IGFBP levels are indicative of a high IGF status. A method of determining the prognosis of existing prostate cancers or of monitoring disease progression involves determining the IGF/PSA status of an individual. Individuals with a high IGF/PSA status (both high IGF status and high PSA levels) tend to develop severe prostate cancer and have a poorer overall prognosis.
    Type: Application
    Filed: March 14, 2001
    Publication date: August 30, 2001
    Inventors: Michael N. Pollak, Meir J. Stampfer, Edward Giovannucci